MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial . Totality of efficacy and safety data re ...
Clinically meaningful MG-ADL response (≥2-point reduction) occurred in 69% of treated patients, exceeding the 53% response rate observed in placebo comparators.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results